Suppr超能文献

美国狼疮的临床管理:基于理赔数据的分析。

Clinical management of lupus in the United States: A claims-based analysis.

机构信息

AMPEL BioSolutions, LLC, Charlottesville, VA 22902, USA; RILITE Research Institute, Charlottesville, VA 22902, USA.

AMPEL BioSolutions, LLC, Charlottesville, VA 22902, USA; RILITE Research Institute, Charlottesville, VA 22902, USA.

出版信息

Semin Arthritis Rheum. 2024 Oct;68:152472. doi: 10.1016/j.semarthrit.2024.152472. Epub 2024 Jun 3.

Abstract

OBJECTIVES

To understand the evaluation and management of patients coded with lupus in the broad clinical community in the United States.

METHODS

Claims data for diagnoses, procedures, medications, and physician specialties were evaluated for three lupus cohorts [lupus nephritis (LN), systemic lupus erythematosus excluding LN (SLE), and cutaneous lupus erythematosus excluding SLE and LN (CLE)] using the EVERSANA claims databases. Identification of patients was based upon the occurrence of lupus-specific codes, with the requirement that a single patient receive a lupus-related ICD code twice within a six-month period.

RESULTS

Using ICD codes, we were able to identify 28,372 patients coded with LN, 82,744 patients coded with SLE, and 13,920 patients coded with CLE, and subsequently evaluate the journey of patients in each group in the year before and after being coded as having a diagnosis of lupus. For the three lupus cohorts, the basis of diagnosis was not always apparent, as clinical features of lupus were not often obtained, autoantibody testing was not usual, biopsies were uncommon and subspecialty involvement was not routine. In addition, a significant increase in laboratory testing, non-lupus diagnoses, emergency department visits and cost during the year before receiving a lupus code suggested uncertainty in disease recognition. Nevertheless, these patients received two separate lupus coding events within a six-month period, supporting a sustained or repeated diagnosis of lupus by the evaluating clinicians. When compared, the three lupus cohorts differed with regard to frequency of laboratory testing, subspecialty care, skin and renal biopsies, and medication management. Moreover, there was an increase in the cost of care of patients coded with lupus compared to a reference patient population both during the year before and after being coded with a diagnosis of lupus.

CONCLUSION

The data present a comprehensive report of the care of patients coded as having a diagnosis of lupus in the United States, including those outside of specialty centers. Despite the unclear basis of diagnosis in some patients, evaluation and management of patients coded as having a diagnosis of lupus in the general care community does not closely follow the recommended guidelines set forth by professional societies.

摘要

目的

了解美国广泛临床社区中编码为狼疮的患者的评估和管理。

方法

使用 EVERSANA 索赔数据库,对三个狼疮队列(狼疮肾炎 (LN)、系统性红斑狼疮不包括 LN (SLE) 和皮肤红斑狼疮不包括 SLE 和 LN (CLE))的诊断、程序、药物和医师专业进行索赔数据评估。通过发生狼疮特异性编码来识别患者,要求每位患者在六个月内两次接受狼疮相关 ICD 编码。

结果

使用 ICD 编码,我们能够识别出 28372 名 LN 编码患者、82744 名 SLE 编码患者和 13920 名 CLE 编码患者,并随后评估每个组中患者在被编码为狼疮诊断前后一年的旅程。对于三个狼疮队列,诊断的基础并不总是明显,因为狼疮的临床特征并不经常获得,自身抗体检测并不常见,活检也不常见,亚专科参与也不常见。此外,在接受狼疮编码前一年,实验室检测、非狼疮诊断、急诊就诊和成本显著增加,表明疾病识别存在不确定性。尽管如此,这些患者在六个月内接受了两次单独的狼疮编码事件,支持评估临床医生对狼疮的持续或反复诊断。在比较时,三个狼疮队列在实验室检测、专科护理、皮肤和肾脏活检以及药物管理方面存在差异。此外,与参考患者群体相比,编码狼疮的患者的护理成本在接受狼疮诊断前后一年都有所增加。

结论

该数据全面报告了美国编码为狼疮诊断的患者的护理情况,包括非专科中心的患者。尽管一些患者的诊断基础不明确,但在普通护理社区中对编码为狼疮诊断的患者的评估和管理并不严格遵循专业协会制定的建议指南。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验